Homologous recombination deficiency, or HRD, is a breakdown in one of the cell’s most important DNA repair systems, and it sits at the center of how several aggressive cancers develop and how they can be treated. When homologous recombination works properly, it fixes dangerous double-strand DNA breaks with high fidelity by copying intact information from a sister chromosome. When the genes running that process are damaged or silenced, the cell loses its most accurate repair option and accumulates mutations at an accelerated pace. That genomic instability drives cancer, but it also creates a vulnerability that oncologists have learned to exploit with targeted drugs.
How Homologous Recombination Repair Works
Your DNA takes hits constantly. Most damage affects only one strand and gets patched easily. A double-strand break, where both rails of the DNA ladder snap, is far more dangerous. The cell has two main options for fixing it: nonhomologous end-joining, which is fast but error-prone, and homologous recombination, which is slower but remarkably precise because it uses a matching copy of the damaged sequence as a template.
Homologous recombination repair (HRR) proceeds through a carefully sequenced series of steps. First, a protein complex recognizes the break and chews back one strand in each direction, exposing single-stranded DNA tails. A coating protein stabilizes those tails, and then a key enzyme called RAD51 is loaded onto them with the help of mediator proteins, forming a structure called a nucleoprotein filament. That filament searches for a matching sequence on the sister chromosome, invades the intact double helix, and uses it as a template for new DNA synthesis. Once the missing information is copied, the strands separate, the gaps are filled, and the chromosome is restored to its original state.
1PubMed Central. Homologous recombination and the repair of DNA double-strand breaksThe whole process depends on dozens of proteins working in sequence. If any critical player is missing or defective, the cell falls back on less accurate repair methods. That is the root of HRD: the high-fidelity option is offline, and the cell accumulates mutations it otherwise would not.
2PubMed Central. How cells ensure correct repair of DNA double-strand breaksThe Genes That Make or Break Homologous Recombination
BRCA1 and BRCA2 get the most public attention, and for good reason. Both are essential to the HRR pathway. BRCA1 helps orchestrate the early damage response and coordinates the handoff to repair machinery, while BRCA2 is directly responsible for loading RAD51 onto single-stranded DNA, the step that enables the homology search. Lose function in either gene and the entire repair chain stalls.
3Trends in Genetics. Homologous Recombination Deficiency: Genes, Repair, and CancerBut BRCA1 and BRCA2 are not the only genes that matter. PALB2 acts as a physical bridge between BRCA1 and BRCA2, stabilizing RAD51 filaments. RAD51 itself carries out the central act of strand invasion. Mutations in either gene compromise homologous recombination and raise cancer risk.
4PubMed Central. RAD51 and PALB2 in precision oncology: Clinical implications for HRD associated breast and ovarian cancersBeyond these, a group of proteins called RAD51 paralogs form two functional complexes that serve non-overlapping roles in mediating RAD51’s activity. They also maintain replication fork stability independently of RAD51. When these paralogs carry inherited mutations, the result can include congenital malformations, bone marrow failure, and early cancer onset, a constellation of problems associated with Fanconi anemia. Even single-copy mutations in these paralog genes have been linked to increased risk of breast and ovarian cancers.
5The Oncologist. Homologous Recombination Deficiency: Cancer Predispositions and Treatment ImplicationsDNA damage signaling genes sit upstream of the repair machinery. ATM and ATR sense damage and relay the alarm, while CHK1 and CHK2 help halt the cell cycle so repair can proceed. Fanconi anemia pathway genes handle a related class of DNA damage called interstrand crosslinks. Defects in any of these categories can produce the same functional outcome as a BRCA mutation: a cell that cannot perform homologous recombination.
6Cancer Research. BRCAness, Homologous Regeneration Deficiencies, and Synthetic LethalityBRCAness and the Broader HRD Landscape
The concept of “BRCAness,” first described in 2004, captures something clinicians noticed early on: some tumors behave exactly like BRCA-mutant cancers even though they carry no BRCA mutation. They respond to the same drugs, they accumulate the same patterns of genomic damage, and they share the same underlying vulnerability. What these tumors have in common is that some other component of the HRR pathway is broken. The deficiency in RAD51, ATR, ATM, CHK1, CHK2, NBS1, FANCD2, FANCA, FANCC, or other HRR-related genes can all produce BRCAness and confer sensitivity to targeted therapies.
6Cancer Research. BRCAness, Homologous Regeneration Deficiencies, and Synthetic LethalityEpigenetic silencing adds another layer. A gene does not need to be mutated to be switched off. Methylation of the BRCA1 promoter region, for instance, can shut down BRCA1 expression without altering the DNA sequence. Tumors with BRCA1 promoter methylation show HRD scores comparable to those carrying actual mutations in HRR genes. Without either methylation or a gene alteration, HRD is rare.
7PubMed Central. Constitutional BRCA1 Methylation is associated with high level of tumoral BRCA1 methylation and homologous recombination deficiency in triple-negative breast cancerReading the Scars That HRD Leaves Behind
When a tumor has been HRD for a while, its genome accumulates distinctive marks. These “genomic scars” persist even if the repair defect is later reversed, which makes them useful as a diagnostic footprint. Three types of scar are widely measured: loss of heterozygosity, where one copy of a chromosomal region is lost; telomeric allelic imbalance, reflecting imbalances near chromosome ends; and large-scale state transitions, which indicate chromosomal rearrangements above a certain size. These three scores are typically summed into a composite HRD score.
8npj precision oncology. Pan-cancer analysis of genomic scar patterns caused by homologous repair deficiency (HRD)Beyond structural scars, HRD tumors leave a characteristic pattern of point mutations. Researchers have identified a specific mutational signature associated with HRD, similar to what is catalogued as COSMIC signature 3. Computational tools can detect this signature from whole-genome sequencing, whole-exome sequencing, or even targeted gene panels, which broadens the range of clinical labs that can look for it.
9PubMed Central. Correlation of homologous recombination deficiency induced mutational signatures with sensitivity to PARP inhibitors and cytotoxic agents10PubMed Central. Mutational signatures reveal ternary relationships between homologous recombination repair, APOBEC, and mismatch repair in gynecological cancers
Only two HRD tests currently hold FDA approval, both combining genomic scar detection with BRCA mutation analysis. Newer methods are emerging, but bringing them into routine clinical use involves challenges around cost, turnaround time, and standardization. A joint consensus recommendation from major pathology organizations has laid out guidelines for how labs should design and validate HRD assays, covering everything from the biomarker components to interpretation caveats and reporting standards.
11PubMed Central. Homologous recombination deficiency (HRD) testing landscape: clinical applications and technical validation for routine diagnostics12PubMed. Recommendations for Clinical Molecular Laboratories for Detection of Homologous Recombination Deficiency in Cancer
One limitation of genomic scar scores is that they are a snapshot of past damage, not a readout of current repair status. A tumor that was HRD when it first developed but later regained repair function (through a reversion mutation, for example) will still carry the old scars. A functional assay that measures whether RAD51 is actively forming repair foci in tumor cells may capture these dynamic changes in real time, potentially identifying which BRCA-mutant tumors have already restored their repair capacity.
13PubMed Central. RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancerWhere HRD Turns Up Across Cancer Types
HRD is most strongly associated with ovarian and breast cancers, but it is far from exclusive to them. A pan-cancer analysis found that HRD is also common in prostate and pancreatic cancers, with metastatic prostate and pancreatic tumors actually showing higher rates of HRD than their primary counterparts, while ovarian and breast tumors showed the opposite pattern.
14Nature Communications. Pan-cancer landscape of homologous recombination deficiencyIn high-grade serous ovarian carcinoma, the most common and lethal ovarian cancer subtype, HRD status is both prognostic and predictive. Tumors with HRD scores at or above a threshold of 63 are enriched for BRCA1/2 mutations and carry a better prognosis than those below. Among those cases, tumors whose HRD stems from genetic alterations fare better than those whose HRD arises from epigenetic changes or unknown causes. In one analysis, nearly all patients with genetic HRD who had no residual visible tumor after surgery survived past a median follow-up of over six years.
15Scientific Reports. Homologous recombination deficiency status-based classification of high-grade serous ovarian carcinomaSurvival differences also vary by mutation type and patient population. In one study of ovarian high-grade serous carcinoma stratified by self-reported race, Black individuals with somatic BRCA2 variants had substantially better survival, while those with germline BRCA1 variants had worse survival compared to non-carriers. Findings like these underscore that HRD is not a single uniform state; the specific gene affected, the type of alteration, and the patient’s background all shape outcomes.
16PubMed Central. Homologous recombination deficiency and survival in ovarian high-grade serous carcinoma by self-reported raceTriple-negative breast cancer has the highest proportion of HRD among breast cancer subtypes. Germline BRCA mutations appear in roughly 10 to 20 percent of TNBC patients, with somatic mutations accounting for another 3 to 5 percent. But a broader group of TNBC tumors exhibit BRCAness without carrying a BRCA mutation, making HRD status useful both as a prognostic marker and as a guide for treatment selection.
17PubMed. Homologous recombination deficiency in triple negative breast cancer18PubMed. Homologous recombination deficiency in triple-negative breast cancer: Multi-scale transcriptomics reveals distinct tumor microenvironments and limitations in predicting immunotherapy response
PARP Inhibitors and Synthetic Lethality
The therapeutic breakthrough that made HRD clinically actionable is a concept called synthetic lethality. Individually, losing homologous recombination or losing PARP enzyme activity is survivable for a cell. Losing both at the same time is not. PARP enzymes help repair single-strand DNA breaks. When PARP is blocked by a drug, those single-strand breaks persist and eventually collapse replication forks into double-strand breaks. A normal cell fixes those with homologous recombination and carries on. An HRD cell cannot, and it dies.
A widely discussed refinement of this model focuses on PARP trapping: the inhibitor does not just prevent PARP from working, it physically locks the PARP protein onto the DNA, creating an obstruction that stalls the replication fork. Resolving that stalled fork requires functional homologous recombination, so BRCA-deficient cells are hit especially hard.
19PubMed Central. The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandingsClinical results bear this out. In ovarian cancer, patients with positive HRD status had median progression-free survival of about 30.5 months versus 16.8 months for HRD-negative patients. Even among those without BRCA mutations, HRD-positive status was linked with better progression-free survival compared to HRD-negative patients.
20PubMed Central. Homologous recombination deficiency status predicts response to platinum-based chemotherapy in Chinese patients with high-grade serous ovarian carcinomaIn triple-negative breast cancer, HRD status predicts response to platinum-containing chemotherapy as well. In one study, patients with HR-deficient tumors achieved pathologic complete response at a rate of about 42 percent compared to 10 percent in non-deficient tumors. In a cisplatin-specific cohort, the gap was even wider: roughly 28 percent versus zero.
21Clinical Cancer Research. Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast CancerAn intriguing angle involves the tumor microenvironment. Cells exposed to severe or prolonged low-oxygen conditions show decreased expression of homologous recombination proteins. In other words, the tumor’s own hypoxic core can temporarily suppress repair, making even tumors without genetic HRD potentially vulnerable to PARP inhibition under certain conditions.
22Cancer Research. Contextual Synthetic Lethality of Cancer Cell Kill Based on the Tumor MicroenvironmentHow Tumors Fight Back
Resistance to PARP inhibitors is a major clinical challenge. The most common escape route is a reversion mutation: the tumor acquires a new mutation that undoes the original BRCA defect, restoring the open reading frame and bringing homologous recombination back online. These reversions are detected in roughly half to 80 percent of BRCA-mutant patients who initially respond but later relapse.
23PubMed Central. BRCA2 reversion mutation-independent resistance to PARP inhibition through impaired DNA prereplication complex functionReversion mutations have been documented in BRCA1, BRCA2, and PALB2 after exposure to platinum chemotherapy or PARP inhibitors. In one autopsy study of a patient with metastatic disease, ten different BRCA2 reversion mutations were found across eleven metastatic sites, illustrating how each metastasis can independently evolve its own resistance solution under drug pressure.
24npj precision oncology. Convergent evolution of BRCA2 reversion mutations under therapeutic pressure by PARP inhibition and platinum chemotherapyBut reversions are not the only escape hatch. In BRCA1-mutant tumors, loss of a protein called 53BP1 can partially restore homologous recombination without correcting the BRCA1 gene itself. 53BP1 normally blocks the DNA end-resection step that kicks off homologous recombination. Remove 53BP1 and the pathway can limp along well enough to survive PARP inhibition.
25PubMed Central. Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumorsThere are also resistance mechanisms entirely independent of restoring homologous recombination, such as changes to the DNA prereplication complex that allow cells to tolerate replication stress without functional HR. This diversity of resistance pathways is why relying on a single targeted therapy indefinitely rarely works and why combining or sequencing treatments is an area of active investigation.
23PubMed Central. BRCA2 reversion mutation-independent resistance to PARP inhibition through impaired DNA prereplication complex functionTargeting the Backup Repair Pathway
When homologous recombination is knocked out, cells lean heavily on an alternative repair process called microhomology-mediated end-joining. The central enzyme in that pathway is polymerase theta (commonly abbreviated POLθ). It is expressed at low levels in healthy tissue but is often overexpressed in HRD cancers. That overexpression makes sense from the tumor’s perspective: it needs POLθ to patch double-strand breaks that HR can no longer handle. But it also creates another synthetic lethality target. Block POLθ in an HR-deficient cell and both major repair routes are gone.
26PubMed. Targeting Polymerase Theta (POLθ) for Cancer TherapyInhibitors targeting either the helicase domain or the polymerase domain of POLθ are currently in clinical trials. Beyond offering a new drug class for HRD tumors, POLθ inhibition could help tackle PARP inhibitor resistance. If a tumor that became resistant to a PARP inhibitor still depends on microhomology-mediated end-joining for survival, blocking POLθ could resensitize it or push it past the point of viability.
27Cancer Research. Exploiting the Microhomology-Mediated End-Joining Pathway in Cancer TherapyHRD and the Immune System
The genomic instability caused by HRD does not just produce structural chaos inside the tumor cell. It also generates neoantigens, novel protein fragments that the immune system can recognize as foreign. A pan-cancer analysis found a broad association between high HRD scores and increased neoantigen production across multiple cancer types, including bladder, breast, head and neck, lung, ovarian, and sarcoma. Tumors with high HRD scores also showed greater immune cell infiltration and a microenvironment more conducive to immune attack.
28PubMed. Pan-cancer analysis reveals homologous recombination deficiency score as a predictive marker for immunotherapy respondersThis raises an appealing possibility: using HRD status to predict which patients might benefit from immune checkpoint inhibitor therapy. Modeling work in breast cancer has suggested that a high HRD score could serve as a marker for identifying checkpoint inhibitor responders. If that holds up in prospective trials, it would expand the clinical utility of HRD testing well beyond PARP inhibitor selection. The connection also hints at combination strategies, pairing a PARP inhibitor to exploit the repair defect with a checkpoint inhibitor to amplify the immune response triggered by the resulting genomic instability.